4.65
Titan Pharmaceuticals Inc De stock is traded at $4.65, with a volume of 77,320.
It is down -5.32% in the last 24 hours and up +21.41% over the past month.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
See More
Previous Close:
$4.9114
Open:
$4.85
24h Volume:
77,320
Relative Volume:
1.83
Market Cap:
$4.21M
Revenue:
$61,000
Net Income/Loss:
$-5.46M
P/E Ratio:
-0.711
EPS:
-6.54
Net Cash Flow:
$-6.76M
1W Performance:
+1.09%
1M Performance:
+21.41%
6M Performance:
+24.00%
1Y Performance:
-29.47%
Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile
Name
Titan Pharmaceuticals Inc De
Sector
Industry
Phone
(650) 244-4990
Address
400 OYSTER POINT BLVD, SAN FRANCISCO
Compare TTNP with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TTNP
Titan Pharmaceuticals Inc De
|
4.65 | 4.21M | 61,000 | -5.46M | -6.76M | -6.54 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-26-19 | Initiated | Maxim Group | Buy |
Nov-10-17 | Downgrade | ROTH Capital | Buy → Neutral |
Titan Pharmaceuticals Inc De Stock (TTNP) Latest News
Titan Medical (NASDAQ:TMDIF) Stock Price Down 2.4% – Here’s Why - Defense World
Merger Alert: Titan Pharmaceuticals Takes Major Step Toward TalenTec Combination with Critical SEC Filing - Stock Titan
Biotech to AI: Bionoid Pharma Makes Bold Pivot with New Identity as AI Maverick Intel - Stock Titan
Biotech Rising Star Conduit Pharmaceuticals Gets Green Light for Nasdaq Capital Market Transfer - Stock Titan
Petros Pharmaceuticals Faces NASDAQ Delisting Despite $10M Cash Position, Plans Appeal - Stock Titan
Conduit Pharmaceuticals Secures Future on Nasdaq: Clears Both Bid Price and Equity Hurdles - Stock Titan
Conduit Pharma Sets 15:1 Reverse Split: Shares Drop to 755,900 Starting May 20 - Stock Titan
Biotech Company Makes Bold Leap into AI: Bionoid Pharma Rebrands as AI Maverick Intel - Stock Titan
HOPE Therapeutics Lands $7.8M Deal to Build National Mental Health Network with Ketamine Treatment Centers - Stock Titan
Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update - Stock Titan
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025 - Stock Titan
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - Stock Titan
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results - Stock Titan
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT - Stock Titan
NRXP Reveals Major Mental Health Expansion Plans at Exclusive Mar-A-Lago Investor Event - Stock Titan
Citius Pharmaceuticals Reveals Growth Strategy at Major Jefferies Healthcare Conference - Stock Titan
Biotech Firm Terns Awards Massive 325,000 Share Options Package to New Key Hires - Stock Titan
Generic Percocet Launch: Elite Pharmaceuticals Targets $317M Pain Management Market - Stock Titan
Trump Executive Order Validates Petros' AI Technology Platform for Revolutionary Drug Access Reform - Stock Titan
Heron Therapeutics Strengthens Leadership: Former Veloxis CEO Takes COO Role with Major Stock Package - Stock Titan
Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership - Stock Titan
X4 Pharmaceuticals Strengthens Team with 450,000 Share Options Grant: Inside the Retention Plan - Stock Titan
Major UK Retail Breakthrough: Sonoma's Natural Acne Treatment to Roll Out Across 1,200 Leading Pharmacies - Stock Titan
Jazz's $935M Chimerix Buyout Targets First-Ever Treatment for Rare Brain Cancer, FDA Verdict Looms - Stock Titan
Vincerx Pharma Announces Complete Liquidation and Nasdaq Exit: What Happens to Your Shares? - Stock Titan
Strategic Win: Phathom Taps 30-Year Pharma Veteran to Drive VOQUEZNA Commercial Success - Stock Titan
US Stocks Likely To Open Higher: Expert Says 'The Selling Pressure Is Starting To Be Exhausted' - Benzinga
Titan Pharma Lands Crucial $1M Backing: Inside the Strategic Investment Deal - Stock Titan
Clinical Data: Nika's ITV-1 Drug Demonstrates Breakthrough Effects in Multiple Diseases - Stock Titan
Keros Eyes Potential Sale: Board Weighs Strategic Options Amid Investor Interest - Stock Titan
Strategic Board Shake-Up: Ex-Pharma CFO and Former Congressman Join Titan Environmental's Expansion Push - Stock Titan
Failed Merger Forces Vincerx Pharma to Begin Company Wind-Down: What's Next for Investors? - Stock Titan
Arrowhead Pharmaceuticals Expands Team with 34,190 RSU Grants to New Hires - Stock Titan
Rigel Strengthens Biotech Team: Strategic Stock Grants Attract Key Talent - Stock Titan
Strategic $2.5M Investment Values Mental Health Clinic Network at $50M: Major Expansion Ahead - Stock Titan
Dogwood Therapeutics Saves Nasdaq Status: $17.5M Cash, Zero Debt After Major Financial Overhaul - Stock Titan
Key Investor Update: Lexicon Pharma Takes Stage at Elite Needham Healthcare Conference - Stock Titan
Citius Secures Strategic $2M Funding to Accelerate LYMPHIR LaunchKey Details Revealed - Stock Titan
NRx Pharmaceuticals Lands Revenue-Generating Mental Health Clinic in Strategic Veterans Care Push - Stock Titan
Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan
aTyr Pharma Strengthens Drug Development Team with New Equity Compensation Package - Stock Titan
Actinium Reveals 3 Breakthrough Programs Targeting Billion-Dollar Markets at Mar-a-Lago Update - Stock Titan
Actinium Expands into $B Market: Expert Reveals Breakthrough Cancer Programs - Stock Titan
$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - StockTitan
Eagle Pharmaceuticals Doubles Anti-Takeover Protection to $20 in Rights Plan Update - Stock Titan
Titan Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Major Shake-up: Universe Pharmaceuticals Announces 40:1 Share ConsolidationWhat It Means For Investors - StockTitan
Petros Pharmaceuticals Targets $38B Self-Care Market with Game-Changing AI Drug Platform - Stock Titan
Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan
NRx Pharmaceuticals Slashes Losses by 33% While Securing $300M+ Potential Deal - Stock Titan
Shuttle Pharma Raises $5.75M: Strategic Boost for Revolutionary Cancer Treatment Trial - Stock Titan
Titan Pharmaceuticals Inc De Stock (TTNP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):